WUXI BIO (02269): Miao Jingwen appointed as non-executive director.
Wu Yibing, Ph.D., has resigned as of November 20, 2024, in an announcement from WuXi Biologics (02269).
WUXI BIO (02269) announces that, effective from November 20, 2024, Dr. Wu Yibing has resigned as a non-executive director and member of the Board's decision-making committee to dedicate more time to other personal matters. Ms. Miao Jingwen has been appointed as a non-executive director and member of the decision-making committee.
Related Articles
Hong Kong IPO and ESG consulting service provider Starrygazey (MARH.US) applies for listing in the US, planning to raise $17 million.
LI NING (02331): Subscription matters for financial products
JENSCARE-B (09877) is expected to have an annual total revenue of approximately 1.05 billion to 1.1 billion yuan.
Hong Kong IPO and ESG consulting service provider Starrygazey (MARH.US) applies for listing in the US, planning to raise $17 million.
LI NING (02331): Subscription matters for financial products
JENSCARE-B (09877) is expected to have an annual total revenue of approximately 1.05 billion to 1.1 billion yuan.
RECOMMEND
Paul Chan Says Hong Kong Has Licensed 11 Virtual Asset Exchanges, Stablecoin Licenses Expected Later This Year
22/01/2026
Ministry Of Finance And Other Departments Introduce Comprehensive Fiscal And Financial Policies To Boost Domestic Demand
22/01/2026
Capital Migration: Five Years On, An In‑Depth Analysis Of China’s 11 High‑Growth Venture Capital Tracks In 2025
22/01/2026
